Want to see XRAY full AI Analyst Report?
Top Page
DENTSPLY SIRONA
(NASDAQ:XRAY)
Select Model
Select Model
Rating:58Neutral
Price Target:
$11.00
▼(-14.93% Downside)
Action:Reiterated
Date:08/07/26
XRAY scores 58 primarily due to weak profitability and declining revenue despite resilient cash flow, alongside increased leverage that limits financial flexibility. Technical indicators are moderately supportive (positive MACD and price above key moving averages), while valuation is helped by a high dividend yield but constrained by a negative P/E. The earnings call supports a mid-range score with maintained guidance and stable non-GAAP profitability, tempered by continued top-line pressure and near-term (Q3) weakness.
Positive Factors
Recurring Consumables and Diversified Dental Portfolio
Recurring procedure-driven consumables and a broad presence across dental disciplines support repeat demand, while the installed equipment base can generate follow-on purchases, service revenue and workflow-related sales over time.
Negative Factors
Persistent Revenue Decline and Net Losses
Several years of declining revenue combined with continuing net losses indicate that the turnaround has not yet restored the earnings base. Persistent top-line pressure can reduce operating leverage and limit the company’s ability to absorb fixed costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Consumables and Diversified Dental Portfolio
Recurring procedure-driven consumables and a broad presence across dental disciplines support repeat demand, while the installed equipment base can generate follow-on purchases, service revenue and workflow-related sales over time.
Read all positive factors
DENTSPLY SIRONA Key Performance Indicators (KPIs)
Any
Adjusted Operating Income by Segment
Measures operating profit for each segment after adjusting out non-recurring items, revealing relative profitability and operational efficiency. This helps identify high-margin growth drivers and segments that may be draining resources or require strategic change.
Measures operating profit for each segment after adjusting out non-recurring items, revealing relative profitability and operational efficiency. This helps identify high-margin growth drivers and segments that may be draining resources or require strategic change.
Data provided by:
The Fly
The FlyDENTSPLY SIRONA (XRAY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.18B
Dividend Yield5.86%
Average Volume (3M)5.74M
Price to Earnings (P/E)―
Beta (1Y)0.60
Revenue Growth-0.76%
EPS Growth42.34%
CountryUS
Employees14,000
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-2.74
Shares Outstanding199,353,880
10 Day Avg. Volume5,552,147
30 Day Avg. Volume5,740,378
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.70
Price to Sales (P/S)0.62
P/FCF Ratio21.91
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$13.88Price Target Upside7.31% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)1.53
Revenue Forecast (FY)$3.58B
DENTSPLY SIRONA Business Overview & Revenue Model
Company Description
Dentsply Sirona Inc. is a global dental products and technologies company serving dental professionals, laboratories, and clinics. It operates across consumables and equipment/technology used in preventive, restorative, and specialty dentistry, of...
How the Company Makes Money
Dentsply Sirona primarily makes money by selling dental consumables and dental equipment/technology to dental professionals and institutions through a mix of direct sales and third‑party distributors. A major revenue stream comes from recurring co...
DENTSPLY SIRONA Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Neutral
The call reflected a mixed but constructive tone: management reported near-term top-line pressures across multiple segments (notably OIS and consumables distributor headwinds in EMEA) and acknowledged tariff and geopolitical uncertainties. Offsetting these challenges were stable adjusted EBITDA and EPS, a one-time $44 million tariff refund that materially improved cash flow and EPS, continued strategic investments in sales, clinical education and R&D, expansion of dealer partnerships, and strong Wellspect performance. Management maintained full-year guidance and emphasized that improvements from the return-to-growth action plan should become more visible in Q4 and into 2027. Given balanced operational progress and strategic momentum against ongoing revenue and regional demand headwinds, the overall message is cautiously optimistic but still in turnaround mode.Positive Updates
Revenue and EPS Stability (Non-GAAP)
Q2 revenue of $898 million; adjusted EPS flat year-over-year at $0.52. Adjusted EBITDA margins were approximately flat YoY despite headwinds.
Negative Updates
Top-Line Decline
Total Q2 revenue declined 4.1% as reported and 6.3% on a constant currency basis. After adjusting for Byte and a planned ~$8 million dealer inventory reduction, revenue declined 3.6% on a constant currency basis.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue and EPS Stability (Non-GAAP)
Q2 revenue of $898 million; adjusted EPS flat year-over-year at $0.52. Adjusted EBITDA margins were approximately flat YoY despite headwinds.
Read all positive updates
Company Guidance
The company maintained its 2026 guidance for net sales of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50 (explicitly excluding the $44 million tariff refund and any incremental tariff impacts), while noting Q3 revenue should decline sequentially due to seasonality and Q3 earnings are expected below Q2 2026 levels excluding the $0.17 per‑share tariff refund benefit; Q2 results included $898 million of revenue (down 4.1% reported, down 6.3% constant currency, and down 3.6% CC after adjusting for Byte and a planned ~$8 million dealer inventory reduction), adjusted EPS of $0.52 (flat year‑over‑year), roughly flat adjusted EBITDA margins, operating cash flow of $99 million versus $48 million prior year, a $44 million tariff refund (≈$0.17/share) that enabled opportunistic repurchases of 1.3 million shares for ≈$12 million (average price below $10), ending cash of $239 million and net debt/EBITDA of 3.2x, and management said it expects the payoff from investments in sales, clinical education and R&D to become increasingly visible beginning in Q4.DENTSPLY SIRONA Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
38
Negative
Cash Flow
56
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.64B | 3.68B | 3.79B | 3.96B | 3.92B | 4.23B |
| Gross Profit | 1.80B | 1.84B | 1.96B | 2.09B | 2.13B | 2.35B |
| EBITDA | 172.00M | -46.00M | -518.00M | 249.00M | -662.00M | 952.00M |
| Net Income | -546.00M | -598.00M | -910.00M | -132.00M | -950.00M | 411.00M |
Balance Sheet | ||||||
| Total Assets | 5.20B | 5.43B | 5.75B | 7.37B | 7.64B | 9.24B |
| Cash, Cash Equivalents and Short-Term Investments | 239.00M | 326.00M | 272.00M | 334.00M | 365.00M | 339.00M |
| Total Debt | 2.31B | 2.47B | 2.27B | 2.30B | 2.15B | 2.29B |
| Total Liabilities | 3.85B | 4.09B | 3.81B | 4.08B | 3.83B | 4.24B |
| Stockholders Equity | 1.35B | 1.34B | 1.94B | 3.29B | 3.81B | 5.00B |
Cash Flow | ||||||
| Free Cash Flow | 143.00M | 104.00M | 281.00M | 228.00M | 368.00M | 515.00M |
| Operating Cash Flow | 319.00M | 235.00M | 461.00M | 377.00M | 517.00M | 657.00M |
| Investing Cash Flow | -173.00M | -132.00M | -197.00M | -89.00M | -138.00M | -358.00M |
| Financing Cash Flow | -265.00M | -80.00M | -302.00M | -307.00M | -329.00M | -379.00M |
DENTSPLY SIRONA Technical Analysis
Negative
12.93
Price Trends
11.99
Negative
11.53
Negative
11.71
Negative
Market Momentum
-0.44
Positive
36.20
Neutral
5.48
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XRAY, the sentiment is Negative. The current price of 12.93 is above the 20-day moving average (MA) of 12.41, above the 50-day MA of 11.99, and above the 200-day MA of 11.71, indicating a bearish trend. The MACD of -0.44 indicates Positive momentum. The RSI at 36.20 is Neutral, neither overbought nor oversold. The STOCH value of 5.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XRAY.
DENTSPLY SIRONA Risk Analysis
DENTSPLY SIRONA disclosed 26 risk factors in its most recent earnings report. DENTSPLY SIRONA reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
DENTSPLY SIRONA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $133.83B | 42.80 | 17.83% | ― | 20.66% | 21.06% | |
79 Outperform | $33.40B | 22.18 | 23.88% | 1.23% | 9.85% | 9.65% | |
65 Neutral | $52.30B | 57.83 | 3.79% | 2.39% | -2.56% | -40.38% | |
58 Neutral | $2.18B | -3.99 | -39.81% | 4.95% | -0.76% | 42.34% | |
57 Neutral | $13.62B | -12.91 | -16.60% | 0.89% | 5.36% | -632.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
XRAY
DENTSPLY SIRONA
10.92
-3.09
-22.06%
BAX
Baxter International
26.34
1.99
8.17%
BDX
Becton Dickinson
192.00
42.70
28.60%
ISRG
Intuitive Surgical
378.81
-89.63
-19.13%
RMD
Resmed
231.52
-51.29
-18.13%
DENTSPLY SIRONA Corporate Events
Business Operations and StrategyExecutive/Board Changes
Dentsply Sirona Appoints John Fortson as New CFO
Positive
Jun 11, 2026
On June 1, 2026, Dentsply Sirona’s board appointed veteran industrial executive John C. Fortson as executive vice president and chief financial officer, with the role to take effect on July 20, 2026, marking a planned leadership change in th...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
DENTSPLY SIRONA Shareholders Back Governance and Incentive Plan
Positive
Jun 4, 2026
At its annual meeting of stockholders held on June 2, 2026, DENTSPLY SIRONA shareholders elected twelve directors to serve until the next annual meeting, with most nominees receiving strong support but director Donald J. Zurbay facing significantl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.